connector enhancer of kinase suppressor of Ras 2Genealiases: CNK2 · KSR2 · MAGUIN · MRXSHG
Q-omics provides the consensus-scored CNKSR2 profile across patient tissues and cancer cell-line models. CNKSR2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CNKSR2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CNKSR2 RNA expression shows 19,852 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where CNKSR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNKSR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNKSR2 survival associations across molecular data types. CNKSR2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNKSR2 RNA expression–survival associations across cancer types. High CNKSR2 expression shows unfavorable associations in KIRP, KICH, UVM and UCEC, but favorable associations in SKCM and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CNKSR2 RNA expression.
This table summarizes CNKSR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CNKSR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNKSR2 shows lower tumor expression in COAD, BLCA, LUAD, LUSC, BRCA and STAD. The COAD box plot shows higher CNKSR2 RNA expression in normal versus tumor tissue (log2 FC = −0.447, t-test p < 0.001).
This table shows molecular features associated with CNKSR2 in patient tissues and cancer cell lines. In patient samples, CNKSR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNKSR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
